Novavax receives $125 million milestone as Sanofi starts Phase 3 flu‑COVID vaccine trial in Europe
Novavax announced that it has been paid $125 million by Sanofi after the fifth patient was dosed in Sanofi’s Phase 3 trial of a combined influenza‑COVID‑19 vaccine in Europe. The trial tests Novavax’s Nuvaxovid together with Sanofi’s high‑dose flu vaccine in adults aged 60 and older. Under the existing collaboration, Novavax can earn a further $75 million when a manufacturing technology transfer is completed around mid‑2027 and up to $225 million if a U.S. launch of the combination product occurs, plus ongoing royalties on sales.
Why it matters
The payment adds to Novavax’s cash flow and confirms the partnership’s revenue potential, while the future milestones could further boost earnings if the trial progresses to U.S. approval. Investors should note that the upcoming $75 million milestone depends on a technology transfer slated for mid‑2027.
Key facts
- 1Novavax received a $125 million milestone payment when the fifth patient was dosed in Sanofi’s Phase 3 trial. prnewswire.com
- 2The Phase 3 trial is being conducted in Europe and evaluates safety and immunogenicity in adults aged 60 and older. investing.com
- 3Novavax can earn an additional $75 million milestone upon completion of a manufacturing technology transfer expected in mid‑2027. prnewswire.com
- 4A further $225 million milestone is payable if a U.S. launch of the combination vaccine occurs after meeting all U.S. clinical and regulatory requirements. contractpharma.com
- 5Novavax’s partnership with Sanofi has generated more than $1 billion in revenue for Novavax to date. investing.com
- 6The global flu and COVID‑19 markets together exceed $10 billion in value. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.